Prof. Dr. Andreas Serra

Department of Internal Medicine and Nephrology, Klinik Hirslanden, Zurich;
Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich

Klinik Hirslanden, ADPKD
Contact

Andreas Serra holds an MD and MPH degree, trained at the University of Bern, University of Alabama in Birmingham and in Boston at the Harvard University. Prof. Serra has completed a postdoctoral fellowship at the Harvard School of Public Health. He is the head of the SUISSE ADPKD (Therapies for autosomal dominant polycystic kidney disease) cohort and co-director of the Swiss TSC (Treatment for Tuberous Sclerosis) network.

Research focus:

• Mammalian target of rapamycin (mTOR) signaling pathway
• Therapies for autosomal dominant polycystic kidney disease (ADPKD)
• Treatment for Tuberous Sclerosis (TSC)